Oslo, 15 July 2021. Lytix Biopharma - a Norwegian immune-oncology company -
announces today the official opening of the Phase II study of intratumoral
injection of LTX-315 in a combination therapy in patients with solid tumors. The
study will be run at MD Anderson Cancer Center in Houston, Texas with Sarina
Piha-Paul as primary investigator. 

"The initiation of the phase II studies in the US marks the starting point for
our most important clinical investigation. I'm very happy that we have reached
this milestone with backing from the world's leading cancer investigators at MD
Anderson Cancer Center", says Dr. Øystein Rekdal, CEO of Lytix Biopharma.

The Phase II clinical study in the US is designed to assess the efficacy of
LTX-315 in several types of solid tumors including melanoma (skin cancer),
metastatic breast cancer and head and neck cancer. The trial will be a
multicenter study including MD Anderson Cancer Center in Texas, which is one of
the world leading cancer hospitals.  

Lytix Biopharma's leading product candidate - LTX-315 - will be evaluated in
combination with the immune checkpoint inhibitor Pembrolizumab, which blocks
tumor cells' ability to inhibit the body's immune response. Results from
earlier-initial studies indicate that the combination of LTX-315 and
Pembrolizumab may work better than Pembrolizumab alone.

"We strongly believe that Lytix' technology represents a missing link in today's
cancer treatment, since it enables the immune system to both identify and
eliminate cancer cells. When we now open the Phase II study to recruit patients,
we are one step closer important clinical responses", he says.

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358, 
E-mail: Oystein.Rekdal@lytixbiopharma.com

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic peptide that has
demonstrated superior abilities to induce polyclonal t-cell responses.